InvestorWire NewsRoom


Articles Category: Biotechnology
Thursday Dec 31, 2020 - 12:59 pm

United Medical Equipment Business Solutions Network Inc. Offers Medication Management App to Support Caregivers

An estimated 7,000 to 9,000 people die every year in the U.S. due to medication errorsA sizeable percentage of individuals dealing with medication mismanagement are olderUnited Medical’s medication app offers 11 functionalities designed for health-care professionals, caregivers, students and family members Each year, in the United States alone, an estimated 7,000 to 9,000 people die due to a medication error while hundreds of thousands of…

Continue Reading

Wednesday Dec 30, 2020 - 12:40 pm

Brain Scientific Inc. (BRSF) Launches Latest Version of NeuroCap at Largest Global Conference for Neuro Specialists

BRSF presented a new version of NeuroCap(TM), a revolutionary disposable EEG headsetLatest version presented to international medical audience includes velcro enhancements for better adhesionBrain Scientific appears well placed to capitalize on growing need for neurodiagnostic procedures Brain Scientific (OTCQB: BRSF) a neurology-focused medical device company, presented updates on its proprietary brain diagnostics technology at AES2020, the virtual annual meeting of the American Epilepsy Society, the…

Continue Reading

Tuesday Dec 29, 2020 - 11:43 am

Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer

A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next yearThe drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that timeThe company,…

Continue Reading

Tuesday Dec 22, 2020 - 12:09 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin

The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patientsFDA modified the trial design to designate overall survival as the trial’s primary endpointThe market for brain tumor therapies is expected to grow at a CAGR of 10% and reach an estimated $1.6 billion in 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a…

Continue Reading

Monday Dec 21, 2020 - 12:59 pm

Predictive Oncology (NASDAQ: POAI) Adjourns Special Virtual Meeting; CEO Requesting Shareholder Vote for Critical Tax-Related Proposal

POAI sent letter to shareholders requesting attendance at virtual Special Meeting on December 30, 2020Meeting will address reincorporation of POAI in NevadaReincorporation expected to save POAI approximately $158,000 annually in state taxesShareholders can vote online or by telephone, detailed instructions outlined in proxy materials Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently sent…

Continue Reading

Friday Dec 18, 2020 - 11:57 am

United Medical Equipment Business Solutions Network Inc. Is ‘One to Watch’

United Medical Equipment focuses on the needs of aging patients and veteran communities, as well as those impacted by the COVID-19 pandemic.The company is a trusted supplier of FDA-approved COVID-19 rapid antibody test kits and personal protective equipment (“PPE”) offering flexible payment terms.United Medical Equipment is led by a team of professionals who have over 25 years of combined experience in business, 10 years in…

Continue Reading

Thursday Dec 17, 2020 - 1:08 pm

Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes

Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics.New approach allows doctors, researchers to predict more accurately which treatments may work better.Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors. Science has discovered that thumbprints and DNA aren’t the only biological elements that make individuals unique. In fact, ears, eyes, tongues and…

Continue Reading

Tuesday Dec 15, 2020 - 2:59 pm

Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry

Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapyPrecision oncology industry forecast to be worth 99.72 billion by 2027 according to recent reportPOAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery Precision oncology is driven by the profile of genetic mutations…

Continue Reading

Friday Dec 11, 2020 - 1:06 pm

CannAssist International (CNSC) Prepares to Take CBD Product Market by Storm

CannAssist International’s Xceptor Labs is active player within CBD-based product sectorGlobal CBD product market is expected to rise in value from $4.6 billion in 2018 to over $23 billion by 2025Xceptor Labs differentiating product range through use, development of proprietary CiBiDinol technologyCiBiDinol technology covers the oil soluble CBD molecule with a water soluble carrier thereby increasing its bioavailability and enabling easier absorption of productXceptor Labs…

Continue Reading

Thursday Dec 10, 2020 - 12:45 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA

CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points.Berubicin IND accepted for review by FDAPhase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or betterAdult Phase 2 trials to commence in Q1 2021 The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ:…

Continue Reading

Thursday Dec 10, 2020 - 12:27 pm

Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report

Financial numbers show revenues stay level, gross margins up and operations expenses down.Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery.POAI subsidiaries all showing progress, growth in key areas. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update…

Continue Reading

Wednesday Dec 09, 2020 - 2:27 pm

RYAH Group Inc. Is ‘One to Watch’

RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients The…

Continue Reading

Wednesday Dec 09, 2020 - 2:01 pm

Brain Scientific Inc. (BRSF) New Management to Play Key Role in Advancing Commercialization, Growing Revenue

BRSF enhances executive team with new strategy, marketing VPs.New market opportunity created with demand for remote EEG testing due to COVID-19.Brain Scientific has developed NeuroCap(TM), a revolutionary, hospital-grade disposable EEG headset. Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, strengthened its executive team with the appointment of two proven sales and marketing figures. The two management additions include Amy Griffith, the new…

Continue Reading

Tuesday Dec 08, 2020 - 1:24 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Is ‘One to Watch’

Imagin Medical Inc. uses the standard levels of care for bladder tumor resection and adds advanced technology combined with an FDA-approved imaging agent to display images side-by-side in real-time to provide better cancer visualization, potentially leading to less recurrenceHospitals can use their existing endoscopic equipment, as the company’s technology is compatible with almost every model on the marketThe i/Blue™ Imaging System can potentially be used…

Continue Reading

Friday Dec 04, 2020 - 12:32 pm

Brain Scientific Inc. (BRSF) Well Positioned Within Growing EEG Equipment Market

Recent report estimates EEG equipment market will grow at 4.5% CAGR reaching $1.99 billion by 2026Driving forces include aging population, technological advances, increased use in neonatal intensive care unitsBRSF well-placed to capitalize on market's robust growth A recent report published by Allied Market Research estimates that the global electroencephalography (“EEG”) equipment market was $1.4 billion in 2018 and is expected to reach $1.99 billion by…

Continue Reading

Tuesday Dec 01, 2020 - 2:37 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancerSince another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to…

Continue Reading

Monday Nov 30, 2020 - 2:47 pm

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

VTGN CEO “even more excited about PH94B's potential to change lives without the risky side effects and safety concerns of benzos”Study results suggest PH94B's mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liabilityCompany making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder…

Continue Reading

Wednesday Nov 25, 2020 - 10:45 am

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsulesIf it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delaysEnrollment in this arm of the study could begin as early as December 2020 AzurRx BioPharma (NASDAQ: AZRX),…

Continue Reading

Wednesday Nov 25, 2020 - 10:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma MultiformeCompany believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the diseaseSeparately, a Phase II adult trial and a first-ever Phase I pediatric trial are…

Continue Reading

Tuesday Nov 24, 2020 - 9:30 am

VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States

VistaGen currently developing three novel drug candidates designed to treat central nervous system disordersAnxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatmentPrevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annumCOVID-19 pandemic has further exacerbated these conditions, with number of patients displaying anxiety symptoms…

Continue Reading

Monday Nov 23, 2020 - 3:17 pm

Brain Scientific Inc. (BRSF) Has Three-Phase Plan to Improve Access to Neurological Care

BRSF is modernizing brain diagnostics with cost-effective, disposable solutions that help minimize risk of spreading diseaseAI-assisted analysis allows for processing of relevant data in real time at high speed for early diagnosis, higher rate of successful treatments Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics by employing cutting-edge tech to bridge the widening gap in access to quality care. BRSF is achieving this through cost-effective…

Continue Reading

Tuesday Nov 17, 2020 - 3:14 pm

Brain Scientific Inc. (BRSF) Offers Stock to Wider Pool of Investors Through Dalmore Group

BRSF announce partnership with Dalmore GroupNew product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemicBrain Scientific shose to extend proposed Reg A+ offering to attract additional investors Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release ( "We are delighted to…

Continue Reading

Tuesday Nov 17, 2020 - 2:55 pm

AzurRx BioPharma Inc. (NASDAQ: AZRX) Making Strides with MS1819 Clinical Trials for Cystic Fibrosis-Associated Pancreatic Insufficiency

Globally it is estimated that 70,000 people suffer from CF, with half the population in the United StatesThe global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis While still a relatively…

Continue Reading

Monday Nov 16, 2020 - 12:28 pm

Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media

CEO expects results that will “build the stock and raise the stock price”POAI focused on positioning TumorGenesis kits to manufacturersHelomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the…

Continue Reading

Wednesday Nov 11, 2020 - 2:12 pm

Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries

Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospectsSchwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates declineTumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segmentsSoluble Biotech, which announced its first major contract in August, is expected…

Continue Reading

Friday Nov 06, 2020 - 1:37 pm

Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits

POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competitionResults garnered from company’s HSC optimization are unparalleled in fieldSoluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused…

Continue Reading

Thursday Nov 05, 2020 - 2:23 pm

VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines

VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disordersPH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorderCompany sees potential to displace benzodiazepines currently being used to treat multiple anxiety disordersStrategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed…

Continue Reading

Wednesday Nov 04, 2020 - 3:07 pm

Brain Scientific Inc. (BRSF) Is ‘One to Watch’

Brain Scientific is a commercial-stage health care company aiming to modernize the brain diagnostics market by employing cutting edge technologies to bridge the widening gap in access to neurological careThe company’s current offerings are the NeuroCap(TM) and NeuroEEG(TM) – two FDA-cleared devices delivered by wholly owned subsidiary MemoryMD Inc.The company’s intellectual property portfolio includes three patents in the U.S., China and EuropeBrain Scientific is developing…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).